Genocea Biosciences Inc. (GNCA) Receives “Buy” Rating from FBR & Co
FBR & Co restated their buy rating on shares of Genocea Biosciences Inc. (NASDAQ:GNCA) in a research note issued to investors on Wednesday morning. The brokerage currently has a $17.00 target price on the stock.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Genocea Biosciences from a buy rating to a hold rating in a report on Wednesday, July 6th. Piper Jaffray Cos. decreased their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an overweight rating on the stock in a report on Thursday, September 29th. Finally, Needham & Company LLC reissued a buy rating and issued a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, September 29th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Genocea Biosciences has a consensus rating of Buy and a consensus target price of $16.96.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 1.81% during trading on Wednesday, reaching $4.34. 194,379 shares of the company were exchanged. Genocea Biosciences has a 52-week low of $2.56 and a 52-week high of $8.20. The firm’s market cap is $122.97 million. The stock’s 50-day moving average is $5.32 and its 200-day moving average is $4.73.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. Equities research analysts predict that Genocea Biosciences will post ($1.63) earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in GNCA. Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $334,000. Alpine Partners VI LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $120,000. TFS Capital LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $133,000. FMR LLC boosted its stake in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock worth $17,401,000 after buying an additional 21,149 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Genocea Biosciences by 4.8% in the second quarter. Franklin Resources Inc. now owns 3,025,300 shares of the company’s stock worth $12,404,000 after buying an additional 138,700 shares during the period. 56.49% of the stock is owned by institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.